Features

The deeper threat to the biopharmaceutical industry may come not from macro-level disruption, but from structural pressures on the industry’s innovation-driven model and the biotech ecosystem that supports it.

How AI and other digital tools are progressing across the bio/pharmaceutical industry is top of mind. Key perspectives on the use and potential of AI and other digital tools were shared at the DCAT Global Summit.

What are key trends for injectable drugs and the related market impact? From switches from IV-administered to subcutaneous drug delivery and increased interest for home and self administration, DCAT Value Chain Insights provides the latest. 

A recent KPMG study of CEOs of large companies, including 400 US companies, found that supply-chain cost reduction and AI integration and upskilling are top priorities of CEOs. How are companies addressing these challenges? 

What is the outlook for biomanufacturing (drug substance)? How is industry capacity trending, and what is the outlook for outsourcing? A recent study by BioPlan Associates reveals key insights.

The Pharmaceutical Research and Manufacturers of America (PhRMA) has filed a legal complaint that challenges the US government’s most-favored-nation drug pricing policy in the GLOBE Model under Medicare Part B.

Which small-molecule drugs are making the mark in 2026 in new drug approvals or in recently or soon-to-be launched drugs? DCAT Value Chain Insights takes an inside look.

The White House is moving to identify new and unused domestic, US-based, and near-shore production capacity to meet a goal of localizing manufacturing of essential medicines.

A recent analysis by Gartner projects low uptake of AI for autonomous supply-chain planning decisions by 2030, but AI does factor into the workflows of the top 25 supply-chain organizations, according to the firm’s annual rankings, but how?

Novo’s CEO Mike Doustdar laid out a strategic growth plan for the company, which included a plan to launch more than five multi-blockbusters by 2030 and expand beyond its obesity and diabetes franchise. Will he and the company be able to deliver?